Provides blockchain-based digital-asset payment, trading and settlement services to financial institutions, trading firms and merchants.
10-K for FY2025, filed Apr 13, 2026ALT5 Sigma Corporation (formerly known as JanOne Inc.) and subsidiaries (collectively, “we,” “us,” the “Company,” or “ALT5”). Through our…View ↗
ALT5 Sigma Canada Inc. provides next-generation, blockchain-powered technologies for tokenization, trading, clearing, settlement, payment…View ↗
ALT5 Sigma Canada group of companies’ products and services are targeted to business two business (“B2B”) customers and not retail…View ↗
Financial technology customers pay setup and monthly maintenance fees; the company also earns trading fees and spreads when customers trade digital assets, with transaction fees collected when the trade is executed.
10-K for FY2025, filed Apr 13, 2026
10-K for FY2025, filed Apr 13, 2026
FY2025 revenue by reportable segment ↗$24.8M
10-K for FY2025, filed Apr 13, 2026
$24.8M ↗| Segment | Share | Revenue |
|---|---|---|
|
Total Reportable Segments
|
50% |
Total Reportable Segments, FY2025
$24.8M Sources
|
|
Segments Total
|
50% |
Segments Total, FY2025
$24.8M Sources
|
Markets its financial services to financial institutions and trading firms, merchants, and payment-processing partners.
10-K for FY2025, filed Apr 13, 2026
No. It lost $344.5M in FY2025.
10-K for FY2025, filed Apr 13, 2026
−$22.9MView ↗
10-K for FY2025, filed Apr 13, 2026
−$344.5MView ↗
10-K for FY2025, filed Apr 13, 2026
−$7.2MView ↗
10-Q for Q2 FY2026, filed Aug 17, 2026
−$229.6MView ↗
8-K, filed Aug 7, 2026
On August 3, 2026, AI Financial Corporation, a Nevada corporation (“we” or “us”), sold its indirect, wholly-owned subsidiary, ALT 5 Sigma…View ↗
8-K, filed Jul 2, 2026
On July 1, 2026, AI Financial Corporation (the “Company”) was notified by The Nasdaq Stock Market, LLC (“Nasdaq”), that it is not in…View ↗
Shrinking. Revenue fell 38% in 4 years, from $40M in FY2021 to $24.8M in FY2025, about 11% a year.
From drug development to fintech
The earlier report focuses on clinical-stage drug development for pain and addiction; the latest describes blockchain-based digital-asset services and classifies biotech as a discontinued operation.
10-K for FY2022, filed Apr 17, 2023 10-K for FY2025, filed Apr 13, 2026
Loading...